InVivo Therapeutics appoints interim CEO, Reynolds resigns
This article was originally published in Scrip
Francis M Reynolds has resigned as chair, chief executive officer and chief financial officer of InVivo Therapeutics due to an unreported medical condition. The Cambridge, Massachusetts-based company's board has appointed Michael J Astrue and Sean Moran as CEO and CFO, respectively. Mr Astrue is currently the non-executive chair of the board at drug development company Vivus. InVivo develops treatments to improve function in individuals paralyzed from traumatic spinal cord injuries.
You may also be interested in...
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.